Tg Therapeutics, Inc. (TGTX): Sean A Power , CFO, Secretary and Treasurer of Tg Therapeutics, Inc. sold 50,426 shares on Jul 5, 2016. The Insider selling transaction was reported by the company on Jul 8, 2016 to the Securities and Exchange Commission. The shares were sold at $5.99 per share for a total value of $302,051.75 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 20, 2016, Sean A Power (CFO, Secretary and Treasurer) sold 10,000 shares at $10.12 per share price.On Jul 10, 2015, William James Kennedy (director) sold 17,000 shares at $17.08 per share price.Also, On May 11, 2015, Biotechnologies S.a.s.u. Lfb (10% owner) purchased 114,855 shares at $6.53 per share price.
Shares of TG Therapeutics Inc (TGTX) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.37 points or -5.81% at $6 with 5,01,179 shares getting traded. Post opening the session at $6.3, the shares hit an intraday low of $5.82 and an intraday high of $6.403 and the price vacillated in this range throughout the day. The company has a market cap of $326 M and the number of outstanding shares has been calculated to be 5,43,39,123 shares. The 52-week high of TG Therapeutics Inc is $19.05 and the 52-week low is $5.8.
Company has been under the radar of several Street Analysts.TG Therapeutics Inc is Initiated by SunTrust to Buy and the brokerage firm has set the Price Target at $18. The Rating was issued on May 27, 2016.
TG Therapeutics Inc. (TG) is a biopharmaceutical company focused on the acquisition development and commercialization of treatments for b-cell malignancies and autoimmune diseases. As of December 31 2014 TG had two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202 an orally available PI3K delta inhibitor. As of December 31 2014 both TG-1101 and TGR-1202 were in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop inhibitors of IRAK4 (interleukin-1 receptor-associated kinase 4) as well as an antibody research program to develop anti-PD-L1 and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies which were in pre-clinical development as of December 31 2014.